BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 28464264)

  • 21. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single institutional non-randomized retrospective comparison between definitive chemoradiotherapy and radical surgery in 82 Japanese patients with resectable esophageal squamous cell carcinoma.
    Yamashita H; Nakagawa K; Yamada K; Kaminishi M; Mafune K; Ohtomo K
    Dis Esophagus; 2008; 21(5):430-6. PubMed ID: 19125797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment and survival outcomes of small cell carcinoma of the esophagus: an analysis of the National Cancer Data Base.
    Wong AT; Shao M; Rineer J; Osborn V; Schwartz D; Schreiber D
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27860114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy.
    Yang GQ; Mhaskar R; Rishi A; Naghavi AO; Frakes JM; Almhanna K; Fontaine J; Pimiento JM; Hoffe SE
    Dis Esophagus; 2019 Aug; 32(8):. PubMed ID: 30597022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in Treatment of T1N0 Esophageal Cancer.
    Semenkovich TR; Hudson JL; Subramanian M; Mullady DK; Meyers BF; Puri V; Kozower BD
    Ann Surg; 2019 Sep; 270(3):434-443. PubMed ID: 31274653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer.
    Barbetta A; Nobel TB; Sihag S; Hsu M; Tan KS; Bains MS; Isbell JM; Janjigian YY; Wu AJ; Bott MJ; Jones DR; Molena D
    Ann Thorac Surg; 2018 Sep; 106(3):864-871. PubMed ID: 29738752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage Esophagectomy After Definitive Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Who Really Benefits from this High-Risk Surgery?
    Watanabe M; Mine S; Nishida K; Yamada K; Shigaki H; Matsumoto A; Sano T
    Ann Surg Oncol; 2015 Dec; 22(13):4438-44. PubMed ID: 25862582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases.
    Lee PC; Port JL; Paul S; Stiles BM; Altorki NK
    Ann Thorac Surg; 2009 Jul; 88(1):186-92; discussion 192-3. PubMed ID: 19559222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.
    Vlacich G; Samson PP; Perkins SM; Roach MC; Parikh PJ; Bradley JD; Lockhart AC; Puri V; Meyers BF; Kozower B; Robinson CG
    Cancer Med; 2017 Dec; 6(12):2886-2896. PubMed ID: 29139215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Esophageal cancer: outcome according to therapeutic strategy].
    Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
    Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer.
    Ji KSY; Thomas SM; Roman SA; Czito B; Anderson KL; Frakes J; Adam MA; Sosa JA; Robinson TJ
    J Gastrointest Surg; 2019 May; 23(5):885-894. PubMed ID: 30374818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road.
    Depypere L; Lerut T; Moons J; Coosemans W; Decker G; Van Veer H; De Leyn P; Nafteux P
    Dis Esophagus; 2017 Jan; 30(1):1-8. PubMed ID: 27704661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.